Indian CDMO Piramal Pharma to up in vitro capabilities at existing site
During a typically quiet holiday break in biotech, Piramal Pharma made some noise, and it’s starting off 2022 with yet another big announcement.
The CDMO will invest millions into creating a high-throughput screening facility that will enhance the already existing in vitro biology capabilities at its Ahmedabad, India drug discovery site. The new expansion is scheduled to go live in Q3 of this year, and couple its biology services with chemistry capabilities already in operation.
The investment comes with the hopes of improving Piramal’s discovery services for its customers, and speeding up the drug discovery cycle times. It also will add new staffers, in hopes of evaluating and screening 1,000 compounds a week. The platforms will be used to target G-protein-coupled receptors (GPCRs) and kinase-targeted therapies among others.
“Assisting customers in the discovery process is synergistic with our efforts to be a patient-centric CDMO,” CEO Peter DeYoung said in a statement. “With this investment, we are enhancing our discovery platform by adding new in vitro biology services to our existing capabilities, making us a more integrated partner.”
At the end of March, Piramal spent $106 million plus future milestones for the Indian peptide API maker Hemmo Pharmaceuticals. The move was considered by the company to be a part of a larger push into contract work in oncology and metabolic therapies, and came with a manufacturing facility in Turbhe that can produce more than 30 APIs and an R&D facility in Thane. The growth in therapies for rare diseases and orphan drugs has also increased the need for peptides, DeYoung has said.
At the end of December, Indian CDMO Yapan Bio announced that it had landed an investment from Piramal Pharma to help enhance its manufacturing arm.
Yapan provides biologic and vaccine scale-up and manufacturing services, including RNA, DNA, recombinant vaccines, gene therapies and monoclonal antibodies. Piramal has taken on a 27.78% stake in the company with the investment. Its goal is to help Yapan keep up the quick pace of the rapidly expanding CDMO space, in part through Piramal’s fill-finish services.
In 2020, Piramal’s parent company consolidated all of its pharma units under one Piramal Pharma umbrella, and put $32 million into its Riverview, MI API plant, which boasts 25,000 square feet. It offered up 20% of the pharma business as a part of a stake sale, giving the CDMO $490 million cash. It also entered a joint venture with Allergan to manufacture the company’s eye health products.
The Indian company recently received recognition at the Confederation of Indian Industry awards, when its Ennore and Pithampur sites were recognized as star champions and challengers.
It is a proud moment for us as we announce that 2 of ours sites have won 3 awards at the prestigious CII Champion and Challenger Awards 2021.
— Piramal Pharma (@PiramalPharma) December 27, 2021
Editor’s Note: For more news and exclusive coverage from the manufacturing beat, subscribe to the Endpoints Manufacturing weekly report in your reader profile.